119 related articles for article (PubMed ID: 25921410)
1. Dose Related Patterns of Ventricular Arrhythmia due to Carvedilol Withdrawal in Patients with Systolic Heart Failure.
Kido K; Brouse SD; Macaulay TE; Charnigo RJ; Anaya P
Curr Drug Saf; 2015; 10(3):227-33. PubMed ID: 25921410
[TBL] [Abstract][Full Text] [Related]
2. Effects of carvedilol on left ventricular remodeling and systolic function in elderly patients with heart failure.
Palazzuoli A; Bruni F; Puccetti L; Pastorelli M; Angori P; Pasqui AL; Auteri A
Eur J Heart Fail; 2002 Dec; 4(6):765-70. PubMed ID: 12453548
[TBL] [Abstract][Full Text] [Related]
3. Effects of carvedilol on left ventricular function and oxidative stress in infants and children with idiopathic dilated cardiomyopathy: a 12-month, two-center, open-label study.
Bajcetic M; Kokic Nikolic A; Djukic M; Kosutic J; Mitrovic J; Mijalkovic D; Jovanovic I; Simeunovic S; Spasic MB; Samardzic R
Clin Ther; 2008 Apr; 30(4):702-14. PubMed ID: 18498919
[TBL] [Abstract][Full Text] [Related]
4. Rapid carvedilol up-titration in hospitalized patients with left ventricular systolic dysfunction--data from the Carvedilol in Hospital: Up-titration Limits after Acute Patients Admission registry.
Martínez-Sellés M; Datino T; Alhama M; Barrueco N; Castillo I; Fernández-Avilés F
J Cardiovasc Med (Hagerstown); 2010 May; 11(5):352-8. PubMed ID: 20154635
[TBL] [Abstract][Full Text] [Related]
5. Aspirin impairs reverse myocardial remodeling in patients with heart failure treated with beta-blockers.
Lindenfeld J; Robertson AD; Lowes BD; Bristow MR;
J Am Coll Cardiol; 2001 Dec; 38(7):1950-6. PubMed ID: 11738299
[TBL] [Abstract][Full Text] [Related]
6. Comparative dose titration responses to the introduction of bisoprolol or carvedilol in stable chronic systolic heart failure.
Hamaad A; Lip GY; Nicholls D; MacFadyen RJ
Cardiovasc Drugs Ther; 2007 Dec; 21(6):437-44. PubMed ID: 17896170
[TBL] [Abstract][Full Text] [Related]
7. Addition of ivabradine to β-blocker improves exercise capacity in systolic heart failure patients in a prospective, open-label study.
Bagriy AE; Schukina EV; Samoilova OV; Pricolota OA; Malovichko SI; Pricolota AV; Bagriy EA
Adv Ther; 2015 Feb; 32(2):108-19. PubMed ID: 25700807
[TBL] [Abstract][Full Text] [Related]
8. Tolerability of carvedilol in patients with heart failure and concomitant chronic obstructive pulmonary disease or asthma.
Kotlyar E; Keogh AM; Macdonald PS; Arnold RH; McCaffrey DJ; Glanville AR
J Heart Lung Transplant; 2002 Dec; 21(12):1290-5. PubMed ID: 12490274
[TBL] [Abstract][Full Text] [Related]
9. Randomised, placebo-controlled trial of carvedilol in patients with congestive heart failure due to ischaemic heart disease. Australia/New Zealand Heart Failure Research Collaborative Group.
Lancet; 1997 Feb; 349(9049):375-80. PubMed ID: 9033462
[TBL] [Abstract][Full Text] [Related]
10. Effect of metoprolol versus carvedilol on outcomes in MADIT-CRT (multicenter automatic defibrillator implantation trial with cardiac resynchronization therapy).
Ruwald MH; Ruwald AC; Jons C; Alexis J; McNitt S; Zareba W; Moss AJ
J Am Coll Cardiol; 2013 Apr; 61(14):1518-26. PubMed ID: 23500269
[TBL] [Abstract][Full Text] [Related]
11. Adherence with once daily versus twice daily carvedilol in patients with heart failure: the Compliance And Quality of Life Study Comparing Once-Daily Controlled-Release Carvedilol CR and Twice-Daily Immediate-Release Carvedilol IR in Patients with Heart Failure (CASPER) Trial.
Udelson JE; Pressler SJ; Sackner-Bernstein J; Massaro J; Ordronneau P; Lukas MA; Hauptman PJ
J Card Fail; 2009 Jun; 15(5):385-93. PubMed ID: 19477398
[TBL] [Abstract][Full Text] [Related]
12. Decrease in plasma brain natriuretic peptide level in the early phase after the start of carvedilol therapy is a novel predictor of long-term outcome in patients with chronic heart failure.
Fujimura M; Akaike M; Iwase T; Yoshida S; Sumitomo Y; Yagi S; Ikeda Y; Hashizume S; Aihara K; Nishiuchi T; Yasumura Y; Matsumoto T
Acta Cardiol; 2009 Oct; 64(5):589-95. PubMed ID: 20058503
[TBL] [Abstract][Full Text] [Related]
13. The large-scale placebo-controlled beta-blocker studies in systolic heart failure revisited: results from CIBIS-II, COPERNICUS and SENIORS-SHF compared with stratified subsets from MERIT-HF.
Wikstrand J; Wedel H; Castagno D; McMurray JJ
J Intern Med; 2014 Feb; 275(2):134-43. PubMed ID: 24118421
[TBL] [Abstract][Full Text] [Related]
14. The Pediatric Randomized Carvedilol Trial in Children with Heart Failure: rationale and design.
Shaddy RE; Curtin EL; Sower B; Tani LY; Burr J; LaSalle B; Boucek MM; Mahony L; Hsu DT; Pahl E; Burch GH; Schlencker-Herceg R
Am Heart J; 2002 Sep; 144(3):383-9. PubMed ID: 12228773
[TBL] [Abstract][Full Text] [Related]
15. Impact of initiating carvedilol before angiotensin-converting enzyme inhibitor therapy on cardiac function in newly diagnosed heart failure.
Sliwa K; Norton GR; Kone N; Candy G; Kachope J; Woodiwiss AJ; Libhaber C; Sareli P; Essop R
J Am Coll Cardiol; 2004 Nov; 44(9):1825-30. PubMed ID: 15519014
[TBL] [Abstract][Full Text] [Related]
16. Heart failure in a district general hospital: are target doses of beta-blockers realistic?
Mehta PA; McDonagh S; Poole-Wilson PA; Grocott-Mason R; Dubrey SW
QJM; 2004 Mar; 97(3):133-9. PubMed ID: 14976270
[TBL] [Abstract][Full Text] [Related]
17. Efficacy and safety of carvedilol in treatment of heart failure with chronic kidney disease: a meta-analysis of randomized trials.
Wali RK; Iyengar M; Beck GJ; Chartyan DM; Chonchol M; Lukas MA; Cooper C; Himmelfarb J; Weir MR; Berl T; Henrich WL; Cheung AK
Circ Heart Fail; 2011 Jan; 4(1):18-26. PubMed ID: 21036889
[TBL] [Abstract][Full Text] [Related]
18. Effects of long-term beta-blocker (metoprolol or carvedilol) therapy on QT variability in subjects with chronic heart failure secondary to ischemic cardiomyopathy.
Piccirillo G; Quaglione R; Nocco M; Naso C; Moisè A; Lionetti M; Di Carlo S; Marigliano V
Am J Cardiol; 2002 Nov; 90(10):1113-7. PubMed ID: 12423713
[TBL] [Abstract][Full Text] [Related]
19. Multiparametric comparison of CARvedilol, vs. NEbivolol, vs. BIsoprolol in moderate heart failure: the CARNEBI trial.
Contini M; Apostolo A; Cattadori G; Paolillo S; Iorio A; Bertella E; Salvioni E; Alimento M; Farina S; Palermo P; Loguercio M; Mantegazza V; Karsten M; Sciomer S; Magrì D; Fiorentini C; Agostoni P
Int J Cardiol; 2013 Oct; 168(3):2134-40. PubMed ID: 23506636
[TBL] [Abstract][Full Text] [Related]
20. Dose-dependent prognostic effect of carvedilol in patients with chronic heart failure--special reference to transcardiac [corrected] gradient of norepinephrine.
Nishiyama K; Tsutamoto T; Yamaji M; Kawahara C; Yamamoto T; Fujii M; Horie M
Circ J; 2009 Dec; 73(12):2270-5. PubMed ID: 19838002
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
